Drugpatentwatch Daily Briefing

Drugpatentwatch Daily Briefing

 Buy Now
Facebook Twitter Pinterest

Finding the upside

DrugPatentWatch serves leading companies ranging from biopharmaceutical R&D to healthcare delivery, and has been cited by CNN, NEJM, Nature Journals, and many other leading publications.

We’ve helped large and small companies and governments around with world with projects such as:

  • Finding and evaluating business opportunities
  • Refining market-entry strategies
  • Anticipating loss of market exclusivity
  • Monitoring emerging competitors
  • Formulary management and budget projections

After years of maintaining DrugPatentWatch as a comprehesive analytics platform, we’re making a distillation of cutting-edge information available to you as a daily newsletter.

Introducing the Daily Briefing


DrugPatentWatch has been publishing critical business intelligence since 2002, so we’ve learned what matters to you.

We’ve served hundreds of clients in more than 70 countries, including investment banks, big/small drug companies, payers, governments, and more…

It is from serving these diverse needs that the Daily Briefing was born.

The purpose of the Daily Briefing is to arm you with objective information so you can gain deep insights into gaps in the market and how they can be exploited.

In addition to our daily updates of patent expirations and other market-changing events, the Daily Briefing includes articles on topics like:

  • Valuation of Pharma Companies: 5 Key Considerations
  • Top 6 issues facing the biotechnology industry
  • Branded Generics: What They Are and Why They’re Profitable

Patents in 134 Countries


Readers outside the United States are covered as well.

The Daily Briefing leverages the robust DrugPatentWatch Business intelligence platform, which includes
patent coverage in 134 countries.

In a single click you can see the international equivalents of each expired patent.

Stay Ahead of the Competition


We track inbound searches to DrugPatentWatch to help you stay on top of what’s moving markets.

Find out what drugs, which companies, and what other content is most popular with our global audience, right now!

Don’t get Left Behind


No need to worry about missed issues.

The Daily Briefing is sent daily, direct to your inbox.

If you want to get caught up on prior Daily Briefings, we have back issues available at your disposal.

Lock in introductory pricing

We plan on increasing the subscription price as we expand our team and invest more into the Daily Briefing.

But, if you subscribe now you can lock in the low introductory rates.

And to make sure you’re happy we offer a free trial.

➤ Get the Daily Briefing

$99/month until you cancel

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top